(June 24, 2025)

Noting that the product has been used in the world since 2013 and was monopolized by a US company that has FDA approval, he said, “Now this product has been indigenized in Iran in cooperation with the Atomic Energy Organization of Iran (AEOI) and the Development Headquarters of Nanotechnology and Micro Technologies.”

“The particle size of this product is less than ten nanometers and can move in the lymphatic system,” Shahcheraq said.

“This product will first be delivered to the AEOI. Then, in nuclear medicine centers, it is labeled with technetium-99 radioisotope a few minutes before it is injected into the patient‘s body. After the product is labeled with a radioisotope, it is injected directly (into the tumor) or subcutaneously (in the lymphatic part) to the patient,” he explained.